{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:10:47Z","timestamp":1779185447379,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Burn-injured patients develop altered metabolic processes, predisposing them to venous thromboembolism and bleeding. Enoxaparin titration for venous thromboembolism prevention in trauma patients is safe, but this approach is not well-defined in burn-injured patients. We hypothesized that titration of enoxaparin in burn patients is safe and does not increase bleeding risk. We compared a fixed dose 30\u00a0mg twice-daily enoxaparin dosing regimen to anti-Xa guided, twice-daily enoxaparin titration. Trough anti-Xa levels were measured and adjusted by 10\u00a0mg intervals, with repeat anti-Xa levels measured prior to administration of the fourth or fifth dose. The starting dose in the titrated group was determined by injury type, patient characteristics, and renal clearance as per American Association of Surgeons in Trauma guidelines. One hundred and fifty-two patients were included. Ninety-three received fixed dosing, and 59 were titrated by anti-Xa levels. There were 16 total incidents of bleeding but no difference between the two groups (P\u00a0=\u2009.67). Univariate analysis revealed no differences in patient demographics or comorbidities between those with and without bleeding. When comparing dosing trends, 14 of 20 patients (70%) initiated at 30\u00a0mg were at goal anti-Xa level on initial check, while 5 (25%) were subtherapeutic, and 1 (5%) was supratherapeutic. Comparatively, 24 of 39 patients (62%) started at 40\u00a0mg were at goal anti-Xa level on initial check, while 9 (23%) were subtherapeutic and 6 (15%) were supratherapeutic. We observed that enoxaparin titration does not significantly increase bleeding risk. Larger studies are needed to confirm these findings and determine their effect on venous thromboembolism prevention.<\/jats:p>","DOI":"10.1093\/jbcr\/iraf104","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:52:41Z","timestamp":1749109961000},"page":"1332-1337","source":"Crossref","is-referenced-by-count":1,"title":["Enoxaparin Titration for Venous Thromboembolism Prophylaxis in the Burn-Injured Patient\u2014A Single Center Experience"],"prefix":"10.1093","volume":"46","author":[{"given":"Kevin","family":"Vega","sequence":"first","affiliation":[{"name":"Department of Surgery, Temple University Hospital , Philadelphia, PA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine at Temple University , Philadelphia, PA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Facility, Temple University Health System , Philadelphia, PA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Facility, Temple University Health System , Philadelphia, PA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Temple University Hospital , Philadelphia, PA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"2025110904205551100_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.burns.2022.06.018","article-title":"Epidemiology of burn injury and the ideal dressing in global burn care\u2014regional differences explored","volume":"49","author":"Opriessnig","year":"2023","journal-title":"Burns J Int Soc Burn Inj"},{"key":"2025110904205551100_ref2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12873-022-00705-6","article-title":"Burn related injuries: a nationwide analysis of adult inter-facility transfers over a six-year period in the United States","volume":"22","author":"Evans","year":"2022","journal-title":"BMC Emerg Med"},{"key":"2025110904205551100_ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-020-0145-5","article-title":"Burn injury","volume":"6","author":"Jeschke","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"2025110904205551100_ref4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0034-1398380","article-title":"Hypercoagulability and venous thromboembolism in burn patients","volume":"41","author":"Meizoso","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"2025110904205551100_ref5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00000658-196802000-00015","article-title":"Pathology of the lung in fatally burned patients","volume":"167","author":"Foley","year":"1968","journal-title":"Ann Surg"},{"key":"2025110904205551100_ref6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.TA.0000057149.42968.1D","article-title":"The prevalence of venous thromboembolism of the lower extremity among thermally injured patients determined by duplex sonography","volume":"55","author":"Wibbenmeyer","year":"2003","journal-title":"J Trauma"},{"key":"2025110904205551100_ref7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/BCR.0b013e318204b2ff","article-title":"Venous thromboembolism in thermally injured patients: analysis of the National Burn Repository","volume":"32","author":"Pannucci","year":"2011","journal-title":"J Burn Care Res Off Publ Am Burn Assoc"},{"key":"2025110904205551100_ref8","first-page":"27","article-title":"Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices","volume":"70","author":"Haut","year":"2011","journal-title":"J Trauma"},{"key":"2025110904205551100_ref9","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1378\/chest.128.5.3372","article-title":"Delays in diagnosis of deep vein thrombosis and pulmonary embolism","volume":"128","author":"Elliott","year":"2005","journal-title":"Chest."},{"key":"2025110904205551100_ref10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cnc.2017.04.012","article-title":"The risks associated with red blood cell transfusion: implications for critical care practice","volume":"29","author":"Sutton","year":"2017","journal-title":"Crit Care Nurs Clin North Am"},{"key":"2025110904205551100_ref11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2008-10-167643","article-title":"Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention","volume":"113","author":"Vamvakas","year":"2009","journal-title":"Blood."},{"key":"2025110904205551100_ref12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.burns.2019.02.011","article-title":"Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients","volume":"45","author":"Cronin","year":"2019","journal-title":"Burns J Int Soc Burn Inj"},{"key":"2025110904205551100_ref13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1592\/phco.24.17.1793.52344","article-title":"Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism","volume":"24","author":"Yogaratnam","year":"2004","journal-title":"Pharmacotherapy."},{"key":"2025110904205551100_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BCR.0b013e318204b346","article-title":"Enoxaparin and antifactor Xa levels in acute burn patients","volume":"32","author":"Lin","year":"2011","journal-title":"J Burn Care Res Off Publ Am Burn Assoc"},{"key":"2025110904205551100_ref15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/TA.0000000000002830","article-title":"Updated guidelines to reduce venous thromboembolism in trauma patients: a western trauma association critical decisions algorithm","volume":"89","author":"Ley","year":"2020","journal-title":"J Trauma Acute Care Surg"},{"key":"2025110904205551100_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irae201","article-title":"Enoxaparin 40mg twice daily with peak anti-Xa adjustments is safe and necessary to achieve therapeutic chemoprophylaxis in burn-injured patients","author":"Pinto","year":"2024","journal-title":"J Burn Care Res"},{"key":"2025110904205551100_ref17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/TA.0000000000003475","article-title":"American Association for the Surgery of Trauma\/American College of Surgeons-Committee on trauma clinical protocol for inpatient venous thromboembolism prophylaxis after trauma","volume":"92","author":"Yorkgitis","year":"2022","journal-title":"J Trauma Acute Care Surg"},{"key":"2025110904205551100_ref18","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamasurg.2016.1662","article-title":"Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma","volume":"151","author":"Ko","year":"2016","journal-title":"JAMA Surg"},{"key":"2025110904205551100_ref19","doi-asserted-by":"crossref","first-page":"I22","DOI":"10.1161\/01.CIR.0000078464.82671.78","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation."},{"key":"2025110904205551100_ref20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the kids-DOTT randomized clinical trial","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA."},{"key":"2025110904205551100_ref21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.21037\/cdt.2016.11.22","article-title":"Incidence and interventions for post-thrombotic syndrome","volume":"6","author":"Farrell","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025110904205551100_ref22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.chest.2023.03.029","article-title":"Evaluation and management of chronic thromboembolic pulmonary hypertension","volume":"164","author":"Yang","year":"2023","journal-title":"Chest."},{"key":"2025110904205551100_ref23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/ACO.0000000000000701","article-title":"Burn injury and blood transfusion","volume":"32","author":"Palmieri","year":"2019","journal-title":"Curr Opin Anaesthesiol"},{"key":"2025110904205551100_ref24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy."},{"key":"2025110904205551100_ref25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40635-023-00582-8","article-title":"Capillary leak and endothelial permeability in critically ill patients: a current overview","volume":"11","author":"Saravi","year":"2023","journal-title":"Intensive Care Med Exp"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/iraf104\/63443534\/iraf104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/46\/6\/1332\/63443534\/iraf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/46\/6\/1332\/63443534\/iraf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T09:21:04Z","timestamp":1762680064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/46\/6\/1332\/8157531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,6]]},"published-print":{"date-parts":[[2025,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/iraf104","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,6]]}}}